Sirolimus
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Sirolimus and local guidelines before prescribing.
Mechanism
mTOR inhibitor immunosuppressant.
Uses
Renal transplant rejection prophylaxis, lymphangioleiomyomatosis.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Hyperlipidaemia, impaired wound healing, proteinuria, mouth ulcers, infection.
Interactions
CYP3A4 and P-gp inhibitors and inducers; ciclosporin increases nephrotoxicity.
Contraindications and cautions
Active infection
Monitoring
Levels, lipids, proteinuria
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Reduce dose in hepatic impairment
Overdose and reversal
Supportive
Special advice
Trough levels; avoid early use after liver transplant.
More from the textbook: uses, cautions and other points
- Treatment: Sirolimus (mTOR inhibitor) stabilises lung function. Avoid oestrogens.
Respiratory: Interstitial Lung Disease - Sirolimus | LAM - stabilises lung function; monitor levels.
Respiratory: Interstitial Lung Disease - Drug interactions - tacrolimus, ciclosporin, sirolimus and everolimus levels are raised by macrolides and azoles and lowered by rifampicin (see the Renal Anatomy, Physiology and Pharmacology chapter) - always check before prescribing .
ID: Hospital infection, the immunocompromised host, vaccination and public health - mTOR inhibitors (sirolimus, everolimus) - poor wound healing, mouth ulcers, high lipids, proteinuria, pneumonitis.
Renal: Anatomy, Physiology and Pharmacology - Sirolimus or everolimus (mTOR inhibitors) - poor wound healing, mouth ulcers, high lipids, proteinuria, pneumonitis; lower skin cancer risk.
Renal: Dialysis and Transplant - Sirolimus / everolimus | mTOR inhibitors; mouth ulcers, poor wound healing, high lipids, pneumonitis; fewer skin cancers.
Renal: Dialysis and Transplant - Switching to mTOR inhibitors (sirolimus, everolimus) can reduce new SCCs; reduce immunosuppression where possible.
Dermatology: Skin lesions and skin cancer - Autoimmune lymphoproliferative syndrome (ALPS) - defective FAS-mediated apoptosis - chronic lymphadenopathy and splenomegaly , autoimmune cytopenias, raised "double-negative" (CD4−CD8−) T cells, lymphoma risk - sirolimus, mycophenolate.
Clinical Immunology: Primary immunodeficiency
Where it is discussed in the book
- Respiratory: Interstitial Lung Disease (2 mentions)
- Renal: Anatomy, Physiology and Pharmacology (1 mention)
- Renal: Dialysis and Transplant (2 mentions)
- Dermatology: Skin lesions and skin cancer (1 mention)
- ID: Hospital infection, the immunocompromised host, vaccination and public health (1 mention)
- Clinical Immunology: Primary immunodeficiency (1 mention)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (1 mention)
- Clinical Genetics: Single-gene, repeat-expansion and mitochondrial disorders (1 mention)
- Integrated respiratory chapter (2 mentions)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (1 mention)
- Pathology: Immunopathology, amyloidosis, genetic and environmental disease (1 mention)